Pfizer (PFE) — Q3 2026 Earnings Preview
Key Points
- Guidance Raised for FY26 Revenue: Pfizer increased its FY26 revenue guidance midpoint by $500M to $60.5B–$62.5B in August, reflecting strong non-COVID product performance and momentum in new launches and acquired products.
- Adjusted EPS Guidance Maintained: FY26 adjusted diluted EPS guidance remains at $2.80–$3.00, absorbing a $0.10 headwind from the Innovent Biologics transaction.
- Non-COVID Portfolio Driving Growth: Launched and acquired products delivered $3.2B in Q2 2026 (+18% YoY), with underlying business growth of +5% YoY excluding COVID products.
- COVID Franchise Headwinds Continue: FY26 COVID revenue guidance was cut to $4B (from $5B), reflecting persistently low infection rates and lower Paxlovid utilization.
- Cost Discipline and Margin Focus: Pfizer announced an additional $2.5B in net cost savings through 2029, targeting $9.7B in total net savings, supporting margin expansion and investment in pipeline assets.
- Upcoming Catalysts: Key near-term readouts include MEVPRO-1 (mevrometostat in prostate cancer), amylin/GLP-1 combo data, and continued progress in obesity (berobenatide) and oncology (Padcev, SV, 4404).
- Tough Y/Y Comparable: Q3 2025 included strong non-COVID growth and a still-significant COVID contribution; Q3 2026 faces a much lower COVID base and higher non-COVID expectations.
Most Important Factors to Watch This Quarter
| Factor | Why It Matters | What to Watch |
|---|---|---|
| Non-COVID Revenue Growth | Core driver of overall growth as COVID fades | Continued double-digit growth in launched/acquired products (Q2: +18% YoY); performance of Eliquis, Padcev, Nurtec, Vyndaqel, Lorbrena |
| COVID Franchise | Still material to total revenue, but declining | Actual Q3 COVID revenue vs. $4B FY guide; any signs of stabilization or further downside |
| Operating Margins & Cost Savings | Margin expansion is key to offsetting LOE headwinds | Progress on $9.7B cost savings plan; gross margin (Q2: 76%), operating margin (Q2: 35%) |
| R&D Pipeline Progress | Investor focus shifting to pipeline execution | Updates on pivotal study starts, key readouts (MEVPRO-1, amylin/GLP-1 combo, berobenatide Phase III enrollment) |
| Guidance Updates | Management's confidence in full-year delivery | Any changes to FY26 revenue/EPS guidance, COVID assumptions, or cost savings targets |
| Capital Allocation | Dividend stability and BD capacity | Dividend maintenance/growth, BD firepower ($6B+), commentary on future M&A priorities |
Quarterly Financial Snapshot — Actuals and Consensus
Pfizer — Quarterly Results and Consensus ($M)
| Quarter | Revenue (Actual) | Revenue (Consensus) | Gross Margin (%) | EBITDA (Actual) | Net Income (Actual) | EPS GAAP (Actual) |
|---|---|---|---|---|---|---|
| Q2 2026 | 15,000 | 14,388 | 76.0 | 6,034 | 3,908 | 0.45 |
| Q1 2026 | 14,500 | 13,802 | 78.6 | 6,329 | 4,137 | 0.52 |
| Q4 2025 | 17,600 | 16,828 | 70.2 | 6,073 | 3,226 | 0.39 |
| Q3 2025 | 16,502 | 16,502 | 73.2 | 6,229 | 3,610 | 0.44 |
Consensus figures rounded to nearest million. Actuals per company filings.
Full-Year Guidance and Consensus
Pfizer — FY26 Guidance vs. Consensus
| Metric | FY26 Guidance (as of Aug 2026) | FY26 Consensus Estimate |
|---|---|---|
| Revenue ($M) | 60,500 – 62,500 | 62,278 |
| Adjusted EPS ($) | 2.80 – 3.00 | |
| Gross Margin (%) | Mid-70s | 75.1 |
| EBITDA ($M) | 24,677 | |
| Net Income ($M) | 16,989 |
Year-on-Year Comparison: Q3 2026 vs. Q3 2025
| Quarter | Revenue ($M) | YoY Growth | Key Drivers / Headwinds |
|---|---|---|---|
| Q3 2026 (est.) | 15,910 | -3.6% | Lower COVID (-), strong non-COVID (+), tough comp |
| Q3 2025 | 16,502 | COVID still material, non-COVID growth |
- Q3 2026 faces a tough comparable: Q3 2025 included higher COVID revenues and strong non-COVID growth. In Q3 2026, COVID is down sharply, so the non-COVID portfolio must deliver to offset the drag.
Segment/Portfolio Commentary
- Launched & Acquired Products: Delivered $3.2B in Q2 2026 (+18% YoY), led by Padcev, Eliquis, Nurtec, Lorbrena, and Vyndaqel. Management expects this group to continue double-digit growth and be the main offset to LOEs.
- COVID Franchise: FY26 guidance now $4B (down from $5B), with most Comirnaty sales expected in Q4. Paxlovid remains volatile and highly correlated to infection rates.
- Oncology: Seagen portfolio up +21% YoY in Q2 (ex one-time items). Padcev continues to expand into new indications; SV and 4404 are key pipeline assets with upcoming readouts.
- Obesity: Berobenatide (monthly GLP-1) advancing through 10 Phase III studies in 2026; first approval targeted for 2028. Early data suggest efficacy competitive with tirzepatide and better than semaglutide.
- Cost Savings: Additional $2.5B in net cost savings targeted through 2029, bringing total to $9.7B. Focus on SI&A, manufacturing optimization, and technology-driven productivity.
Guidance Table — FY26 (as of August 2026)
| Metric | Guidance (Aug 2026) | Context Notes |
|---|---|---|
| Revenue ($M) | 60,500 – 62,500 | Midpoint raised by $500M in Q2; reflects strong non-COVID, lower COVID |
| Adjusted EPS ($) | 2.80 – 3.00 | Unchanged; absorbs $0.10 IPR&D charge from Innovent deal |
| COVID Revenue ($M) | ~4,000 | Down from $5B prior; low infection rates |
| Gross Margin (%) | Mid-70s | Supported by cost savings, product mix |
| Operating Margin (%) | Q2 actual: 35% | |
| SI&A + R&D Expenses ($M) | Ongoing cost discipline, incremental savings targeted | |
| Dividend | Maintain and grow over time | Commitment to dividend stability |
Management Commentary — Recent Tone and Priorities
- On Non-COVID Growth: "Our commercial teams are performing with excellence and precision... launched and acquired products delivered $3.2B in revenues and grew 18% operationally in the quarter."
- On COVID: "Low COVID-19 incidence could continue to limit Paxlovid utilization. Our plan also assumes that the majority of Comirnaty sales will occur toward year-end, consistent with the vaccination season."
- On Cost Savings: "We now expect approximately $9.7 billion in total net savings from this program through 2029."
- On Pipeline: "We have clear line of sight to our aim of delivering a risk-adjusted high single-digit revenue CAGR from year-end 2028 through year-end 2033."
- On Capital Allocation: "We remain committed to disciplined capital allocation with a continued focus on maintaining and over the long term, growing our dividend while preserving balance sheet strength and flexibility."
What Changed Since Last Year
- Revenue Guidance Raised: FY26 revenue midpoint increased by $500M in August, driven by strong non-COVID performance.
- COVID Revenue Cut: FY26 COVID revenue guidance reduced to $4B, reflecting ongoing weak demand.
- Cost Savings Target Increased: Total net cost savings target raised to $9.7B through 2029.
- Pipeline Progress: Multiple pivotal study starts and key readouts in obesity and oncology; berobenatide Phase III program ramping up.
- Dividend Commitment Reiterated: Management continues to emphasize dividend maintenance and eventual growth.
Summary and Conclusions
- Pfizer enters Q3 2026 earnings with positive momentum in its non-COVID portfolio, offsetting persistent COVID headwinds.
- The company raised its FY26 revenue guidance midpoint to $61.5B, reflecting strong execution in new launches and acquired products.
- Adjusted EPS guidance is unchanged at $2.80–$3.00, with cost savings and margin expansion remaining top priorities.
- Key investor focus areas for the upcoming print are: non-COVID revenue growth, COVID franchise trajectory, margin/cost discipline, pipeline execution (notably in obesity and oncology), and any updates to guidance or capital allocation.
- Year-on-year comparables are challenging due to the sharp decline in COVID revenue, so the market will be looking for evidence that the core business can sustain growth and offset LOE and COVID pressures.
- Management’s tone remains confident, with a clear strategy to drive high single-digit revenue CAGR post-2028 through pipeline execution and disciplined capital deployment.
In summary: For the next earnings report, the Street will be focused on whether Pfizer can continue to deliver strong non-COVID growth, maintain cost discipline, and provide visibility on pipeline catalysts and margin expansion, all while navigating a tough comparable and ongoing COVID headwinds.
